Connect Biopharma reported positive phase 3 results for its eczema drug candidate in a 52-week dataset, positioning the company’s therapy as a potential Dupixent challenger. The update centers on improvements across multiple endpoints in the trial, supporting Connect’s view that its molecule may deliver advantages in long-term disease control. The report strengthens Connect’s clinical case as it pursues late-stage confirmation in atopic dermatitis, a market where efficacy breadth, durability and patient-relevant outcomes influence payer and prescribing decisions. For biotech investors and partners, the phase 3 readout increases the odds of regulatory momentum, while also sharpening competitive scrutiny around head-to-head expectations and how the data profile translates into differentiation.